SOLUTIONS PRODUCTS INNOVATION INVESTORS ESG
0
Add to list
GB COVID-19 Ag POCT
Cat. No. 4ECO101E
More details>
(3 items)
SOLUTIONS PRODUCTS INNOVATION INVESTORS ESG About GBC Our Brands R&D Media Join us Contact us
English 繁體中文
Menu
About Us
Reporting
Corporate Governance
FAQ
Investor News
Select Year:
{{news_year}}
{{y}}
{{n.a_date}}
{{n.a_title}}
Find Out More
Click for all news
COME CONNECT WITH US
投資者關係聯絡人 / 發言人
Frank Lin
G.M.
Phone:+886-3-577-9221 ext. 204
FAX:+886-3-577-9227
E-mail:frank.lin@gbc.com.tw
投資服務代理機構
First Securities
Phone:02-2563-5711
FAX:02-2563-5722
E-mail:tunghua.ho@firstsec.com.tw
Reporting
Financial Statements
Select Year:
{{fr_year}}
{{y}}
{{f["f_name_"+lang]}}
Investor News
Select Year:
{{news_year}}
{{y}}
{{n.a_date}}
{{n.a_title}}
More
Back to previous page
{{p+1}}
{{nshow.a_date}}
{{nshow.a_title}}
Back to previous page

Corporate Governance
Organization
Director
T.C. Lin
General Biologicals Corp. Chairman & CEO
Danner Lab Inc Chairman & CEO
Pacgen Life Science Chairman & CEO
CurieMed Corporation Chairman & CEO
GB GENES CORP. Board director
Taiwan Genomic Industry Alliance Inc. Board Director
Ace Medical Technology Co., Ltd Board Director
Pi-Hua Chen
CHLITINA Holding Limited. Chairman

Representative of Juristic Person of General Biologicals Corp.
Frank Lin
General Biologicals Corp. General Manager
Director of General Biologicals Corp.
GB GENES CORP. Chairman
Director of GB GENES CORP.
Representative of Juristic Person of GB GENES CORP.
Representative of Juristic Person of Viarich Biotechnology Co., Ltd
Independent Director
Ted Chaung
Chief Technology Officer, SCH Biosciences Co. Ltd.
Independent Director, General Biologicals Corp.
Jen-Leigh Wu
Academia Sinica Visiting Chair Professor
NCKU Adjunct Professor
Moderator of the Ministry of Science and Technolohy
NTOU National Taiwan Ocean University Chair Professor
Independent Director, PRIT Biotech Co. Ltd.
Independent Director, General Biologicals Corp.
Cheryl Lin
President, Glonova Co.
Consultant, T-TOP Clinical Research Co.
Director, Yolk Partners Co.
Independent Director, General Biologicals Corp.
Steve, H. S. Kuo
The Ambassador-at-large of Taiwan
Acer Medical Inc./Independent Director and Compensation Committee
Independent Director, General Biologicals Corp.
FAQ
What is GBC's main business?
GBC is a world-leading supplier of in vitro diagnostics and solutions, mainly engaged in the R&D, manufacturing, marketing and service of in vitro diagnostics. At present, the company's products cover three main areas: in vitro diagnostics, life science (Life Science) and services, drugs and biological consumer products, and has the most complete product line in the same industry in China. The company's products and solutions have been used in more than 40 countries and regions around the world.
How big is the company now?
In 2021, the company has 120 employees worldwide.
How can I access the company's financial statements?
The electronic version of the company's financial report can be accessed on the website of the Public Information Observatory (https://mops.twse.com.tw) by entering the company code "4117" to view relevant information.
About Us
GBC was founded in 1984 by the Taiwan Government to develop the first In-vitro Diagnostic (IVD) HBV kit using RIA-based technology as part of Taiwan's nationwide Liver Disease Prevention Program.
GBC has since started researching and developing Hepatitis and Retrovirus (HIV) across various platforms — from RIA, ELISA (Immunoassay) and Real-Time PCR (Molecular) to CTC (Circulating Tumor Cell).

With an expanding range of products including Tumor markers, Fertility, Torch, and Thyroid tests, GBC now has two R&D Centers (Hsin Chu, Taiwan and San Diego, USA) as well as a sales and marketing office in China.

The company has also entered the consumable products market with their brand ‘oh care’ — a range of oral care products for infants and adults that uses the P113 peptide ingredient.
About GBC
{{f["f_name_"+lang]}}